866-997-4948(US-Canada Toll Free)

Ovarian Cancer - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Ovarian Cancer

No. of Pages : 1887 Pages

Ovarian Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 15, 115, 119, 7, 195, 31 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 11, 34 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
Introduction 13
Ovarian Cancer Overview 14
Therapeutics Development 15
Ovarian Cancer - Therapeutics under Development by Companies 17
Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 41
Ovarian Cancer - Pipeline Products Glance 44
Ovarian Cancer - Products under Development by Companies 48
Ovarian Cancer - Products under Investigation by Universities/Institutes 81
Ovarian Cancer - Companies Involved in Therapeutics Development 85
Ovarian Cancer - Therapeutics Assessment 371
Drug Profiles 451
Ovarian Cancer - Dormant Projects 1775
Ovarian Cancer - Discontinued Products 1809
Ovarian Cancer - Product Development Milestones 1816
Appendix 1829

List of Tables
Number of Products under Development for Ovarian Cancer, H2 2016 72
Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2016 73
Number of Products under Development by Companies, H2 2016 75
Number of Products under Development by Companies, H2 2016 (Contd..1) 76
Number of Products under Development by Companies, H2 2016 (Contd..2) 77
Number of Products under Development by Companies, H2 2016 (Contd..3) 78
Number of Products under Development by Companies, H2 2016 (Contd..4) 79
Number of Products under Development by Companies, H2 2016 (Contd..5) 80
Number of Products under Development by Companies, H2 2016 (Contd..6) 81
Number of Products under Development by Companies, H2 2016 (Contd..7) 82
Number of Products under Development by Companies, H2 2016 (Contd..8) 83
Number of Products under Development by Companies, H2 2016 (Contd..9) 84
Number of Products under Development by Companies, H2 2016 (Contd..10) 85
Number of Products under Development by Companies, H2 2016 (Contd..11) 86
Number of Products under Development by Companies, H2 2016 (Contd..12) 87
Number of Products under Development by Companies, H2 2016 (Contd..13) 88
Number of Products under Development by Companies, H2 2016 (Contd..14) 89
Number of Products under Development by Companies, H2 2016 (Contd..15) 90
Number of Products under Development by Companies, H2 2016 (Contd..16) 91
Number of Products under Development by Companies, H2 2016 (Contd..17) 92
Number of Products under Development by Companies, H2 2016 (Contd..18) 93
Number of Products under Development by Companies, H2 2016 (Contd..19) 94
Number of Products under Development by Companies, H2 2016 (Contd..20) 95
Number of Products under Development by Companies, H2 2016 (Contd..21) 96
Number of Products under Development by Companies, H2 2016 (Contd..22) 97
Number of Products under Investigation by Universities/Institutes, H2 2016 98
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 99
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 100
Comparative Analysis by Late Stage Development, H2 2016 101
Comparative Analysis by Clinical Stage Development, H2 2016 102
Comparative Analysis by Early Stage Development, H2 2016 103
Comparative Analysis by Unknown Stage Development, H2 2016 104
Products under Development by Companies, H2 2016 105
Products under Development by Companies, H2 2016 (Contd..1) 106
Products under Development by Companies, H2 2016 (Contd..2) 107
Products under Development by Companies, H2 2016 (Contd..3) 108
Products under Development by Companies, H2 2016 (Contd..4) 109
Products under Development by Companies, H2 2016 (Contd..5) 110
Products under Development by Companies, H2 2016 (Contd..6) 111
Products under Development by Companies, H2 2016 (Contd..7) 112
Products under Development by Companies, H2 2016 (Contd..8) 113
Products under Development by Companies, H2 2016 (Contd..9) 114
Products under Development by Companies, H2 2016 (Contd..10) 115
Products under Development by Companies, H2 2016 (Contd..11) 116
Products under Development by Companies, H2 2016 (Contd..12) 117
Products under Development by Companies, H2 2016 (Contd..13) 118
Products under Development by Companies, H2 2016 (Contd..14) 119
Products under Development by Companies, H2 2016 (Contd..15) 120
Products under Development by Companies, H2 2016 (Contd..16) 121
Products under Development by Companies, H2 2016 (Contd..17) 122
Products under Development by Companies, H2 2016 (Contd..18) 123
Products under Development by Companies, H2 2016 (Contd..19) 124
Products under Development by Companies, H2 2016 (Contd..20) 125
Products under Development by Companies, H2 2016 (Contd..21) 126
Products under Development by Companies, H2 2016 (Contd..22) 127
Products under Development by Companies, H2 2016 (Contd..23) 128
Products under Development by Companies, H2 2016 (Contd..24) 129
Products under Development by Companies, H2 2016 (Contd..25) 130
Products under Development by Companies, H2 2016 (Contd..26) 131
Products under Development by Companies, H2 2016 (Contd..27) 132
Products under Development by Companies, H2 2016 (Contd..28) 133
Products under Development by Companies, H2 2016 (Contd..29) 134
Products under Development by Companies, H2 2016 (Contd..30) 135
Products under Development by Companies, H2 2016 (Contd..31) 136
Products under Development by Companies, H2 2016 (Contd..32) 137
Products under Investigation by Universities/Institutes, H2 2016 138
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 139
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 140
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 141
Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H2 2016 142
Ovarian Cancer - Pipeline by 4SC AG, H2 2016 143
Ovarian Cancer - Pipeline by AB Science SA, H2 2016 144
Ovarian Cancer - Pipeline by AbbVie Inc, H2 2016 145
Ovarian Cancer - Pipeline by AbGenomics International Inc, H2 2016 146
Ovarian Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 147
Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 148
Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 149
Ovarian Cancer - Pipeline by Aduro BioTech Inc, H2 2016 150
Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016 151
Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 152
Ovarian Cancer - Pipeline by Advaxis Inc, H2 2016 153
Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 154
Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016 155
Ovarian Cancer - Pipeline by Alchemia Ltd, H2 2016 156
Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016 157
Ovarian Cancer - Pipeline by Almac Discovery Ltd, H2 2016 158
Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H2 2016 159
Ovarian Cancer - Pipeline by Alteogen Inc, H2 2016 160
Ovarian Cancer - Pipeline by Ambrx Inc, H2 2016 161
Ovarian Cancer - Pipeline by Amgen Inc, H2 2016 162
Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 163
Ovarian Cancer - Pipeline by ANP Technologies Inc, H2 2016 164
Ovarian Cancer - Pipeline by AntiCancer Inc, H2 2016 165
Ovarian Cancer - Pipeline by Antoxis Ltd, H2 2016 166
Ovarian Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016 167
Ovarian Cancer - Pipeline by Aphios Corp, H2 2016 168
Ovarian Cancer - Pipeline by Aposense Ltd, H2 2016 169
Ovarian Cancer - Pipeline by Aprea AB, H2 2016 170
Ovarian Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 171
Ovarian Cancer - Pipeline by arGEN-X BV, H2 2016 172
Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 173
Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 174
Ovarian Cancer - Pipeline by Arno Therapeutics Inc, H2 2016 175
Ovarian Cancer - Pipeline by Arog Pharmaceuticals Inc, H2 2016 176
Ovarian Cancer - Pipeline by ArQule Inc, H2 2016 177
Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 178
Ovarian Cancer - Pipeline by Arvinas Inc, H2 2016 179
Ovarian Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 180
Ovarian Cancer - Pipeline by Astellas Pharma Inc, H2 2016 181
Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 182
Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2016 183
Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2016 184
Ovarian Cancer - Pipeline by Athenex Inc, H2 2016 185
Ovarian Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 186
Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 187
Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2016 188
Ovarian Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 189
Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 190
Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 191
Ovarian Cancer - Pipeline by Bayer AG, H2 2016 192
Ovarian Cancer - Pipeline by BeiGene Ltd, H2 2016 193
Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 194
Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2016 195
Ovarian Cancer - Pipeline by BioMoti Ltd, H2 2016 196
Ovarian Cancer - Pipeline by Bionomics Ltd, H2 2016 197
Ovarian Cancer - Pipeline by BioNTech AG, H2 2016 198
Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016 199
Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 200
Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2 2016 201
Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 202
Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 203
Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016 204
Ovarian Cancer - Pipeline by Cavion LLC, H2 2016 205
Ovarian Cancer - Pipeline by Cellceutix Corp, H2 2016 206
Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 207
Ovarian Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 208
Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016 209
Ovarian Cancer - Pipeline by Celon Pharma SA, H2 2016 210
Ovarian Cancer - Pipeline by Celprogen Inc, H2 2016 211
Ovarian Cancer - Pipeline by Celsion Corp, H2 2016 212
Ovarian Cancer - Pipeline by Celyad SA, H2 2016 213
Ovarian Cancer - Pipeline by Ceronco Biosciences, H2 2016 214
Ovarian Cancer - Pipeline by CerRx Inc, H2 2016 215
Ovarian Cancer - Pipeline by Cerulean Pharma Inc, H2 2016 216
Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 217
Ovarian Cancer - Pipeline by Cielo Therapeutics Inc, H2 2016 218
Ovarian Cancer - Pipeline by Clovis Oncology Inc, H2 2016 219
Ovarian Cancer - Pipeline by CohBar Inc, H2 2016 220
Ovarian Cancer - Pipeline by Coherus BioSciences Inc, H2 2016 221
Ovarian Cancer - Pipeline by Commence Bio Inc, H2 2016 222
Ovarian Cancer - Pipeline by Compliment Corp, H2 2016 223

List of Figures
Number of Products under Development for Ovarian Cancer, H2 2016 72
Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2016 73
Number of Products under Development by Companies, H2 2016 74
Number of Products under Investigation by Universities/Institutes, H2 2016 98
Comparative Analysis by Late Stage Development, H2 2016 101
Comparative Analysis by Clinical Stage Development, H2 2016 102
Comparative Analysis by Early Stage Products, H2 2016 103
Assessment by Monotherapy Products, H2 2016 428
Assessment by Combination Products, H2 2016 429
Number of Products by Top 10 Targets, H2 2016 430
Number of Products by Stage and Top 10 Targets, H2 2016 430
Number of Products by Top 10 Mechanism of Actions, H2 2016 465
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 465
Number of Products by Top 10 Routes of Administration, H2 2016 504
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 504
Number of Products by Top 10 Molecule Types, H2 2016 506
Number of Products by Stage and Top 10 Molecule Types, H2 2016 506

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *